Hikma launches Clobazam oral suspension and Clobazam tablets
Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi
Hikma’s Clobazam is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
According to IQVIA, US sales of Clobazam oral suspension were approximately $260 million and of Clobazam tablets were approximately $601 million in the 12 months ending September 2018.
Brian Hoffmann, President, Generics Division, said: “We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients’ access to this important medicine.”